RxDoctor Payments Data

Lance Wallace, MD

Internal Medicine · Matteson, ILNPI 1538100128

Payments from drug & device makers

$9,502in general payments, 2019–2025

Across 532 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Pfizer$1K
  • Boehringer Ingelheim$934
  • Novo Nordisk$770
  • GSK$596
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$9,461100%
  • Education$410%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,502 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$117,563
Medicare patients
213
Services billed
1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban304$170,582
JardianceEmpagliflozin90$100,347
JanuviaSitagliptin Phosphate70$90,803
OzempicSemaglutide33$47,748
FarxigaDapagliflozin Propanediol35$41,519
TrulicityDulaglutide11$17,949
Breo ElliptaFluticasone/Vilanterol21$12,194
NuedextaDextromethorphan Hbr/Quinidine12$8,793
Atorvastatin Calcium948$8,136
SymbicortBudesonide/Formoterol Fumarate20$6,632
XareltoRivaroxaban13$6,381
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$6,022
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,862
Amlodipine Besylate735$4,404
Memantine Hcl189$3,587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,042$170,582304 claims
Boehringer IngelheimJardiance$934$100,34790 claims
MerckJanuvia$371$90,80370 claims
AstraZenecaFarxiga, Symbicort$1,338$48,15155 claims
Novo NordiskOzempic$770$47,74833 claims
Lilly USA, LLCTrulicity$1,223$17,94911 claims
GSKBreo Ellipta$596$12,19421 claims
Avanir Pharmaceuticals, Inc.Nuedexta$25$8,79312 claims
Johnson & JohnsonXarelto$479$6,38113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Matteson

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →